Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28 USD | -0.39% | -0.57% | -0.32% |
Sales 2024 * | 2.66B 222B | Sales 2025 * | 2.95B 246B | Capitalization | 12.63B 1,053B |
---|---|---|---|---|---|
Net income 2024 * | 1.05B 87.88B | Net income 2025 * | 1.2B 100B | EV / Sales 2024 * | 6.91 x |
Net Debt 2024 * | 5.75B 479B | Net Debt 2025 * | 5.93B 494B | EV / Sales 2025 * | 6.29 x |
P/E ratio 2024 * |
11.9
x | P/E ratio 2025 * |
10.3
x | Employees | - |
Yield 2024 * |
3.14% | Yield 2025 * |
3.42% | Free-Float | 95.08% |
Latest transcript on Royalty Pharma plc
1 day | -0.39% | ||
1 week | -0.57% | ||
Current month | -7.80% | ||
1 month | -7.38% | ||
3 months | -3.81% | ||
6 months | +2.75% | ||
Current year | -0.32% |
Managers | Title | Age | Since |
---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 60 | 01/96/01 |
Terrance Coyne
DFI | Director of Finance/CFO | 42 | 01/10/01 |
Eric Schneider
CTO | Chief Tech/Sci/R&D Officer | - | 21/23/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
FOU | Founder | 71 | 01/96/01 |
Errol de Souza
BRD | Director/Board Member | 70 | 01/20/01 |
David Hodgson
BRD | Director/Board Member | 67 | 23/22/23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.98% | 215 M€ | +10.68% | - | |
0.51% | 5 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 28 | -0.39% | 1,748,254 |
25/24/25 | 28.11 | +0.46% | 3,308,739 |
24/24/24 | 27.98 | +0.58% | 2,578,317 |
23/24/23 | 27.82 | 0.00% | 4,682,024 |
22/24/22 | 27.82 | -1.21% | 2,720,444 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.32% | 12.63B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- RPRX Stock